

PRESS RELEASE



ExonHit will participate to the Paris Smallcap Event on April 27 & 28

Paris, France – April 16, 2009 – ExonHit Therapeutics (Alternext: ALEHT), a fast emerging healthcare player developing innovative blood-based diagnostic tests and therapeutics for neurodegenerative and cancer indications, today announced its participation to the fourth edition of the Smallcap Event to be held in Paris on April 27 & 28.

The Smallcap Event is a forum dedicated to meetings between institutional investors and companies listed on NYSE Euronext. The conference will take place at the Pullman Hotel Tour Eiffel, 18 Avenue Suffren, 75 015 Paris.

ExonHit Therapeutics will be located at the Invest Securities stand. During these two days, fund managers will have the opportunity to meet Dr. Loïc Maurel, President of the Management Board of ExonHit and Philippe Rousseau, Chief Financial Officer, to learn more about the Company, its latest developments and its strategic outlook for the remainder of 2009 and beyond.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood-based diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

ExonHit Therapeutics

Media Contact

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com

Investor Contact

Philippe Rousseau, CFO
+1 240 404 0191
philippe.rousseau@exonhit.com